These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33002195)

  • 1. Neoadjuvant immunotherapy for melanoma.
    Lee AY; Brady MS
    J Surg Oncol; 2021 Mar; 123(3):782-788. PubMed ID: 33002195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
    Long GV; Menzies AM; Scolyer RA
    J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
    Pelster MS; Amaria RN
    Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant immunotherapy for melanoma.
    Thomas D; Bello DM
    J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant immunotherapy in nonsmall cell lung cancer.
    Pall G
    Curr Opin Oncol; 2021 Jan; 33(1):59-63. PubMed ID: 33229874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.
    O'Donnell JS; Hoefsmit EP; Smyth MJ; Blank CU; Teng MWL
    Clin Cancer Res; 2019 Oct; 25(19):5743-5751. PubMed ID: 31040150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.
    Herrscher H; Robert C
    Curr Opin Oncol; 2020 Mar; 32(2):106-113. PubMed ID: 31876547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Treatments for Advanced Resectable Melanoma.
    Liu JY; Lowe M
    J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
    Ferraresi V; Vari S
    Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Adjuvant and Neoadjuvant Therapy for Melanoma.
    Sierra-Davidson K; Boland GM
    Hematol Oncol Clin North Am; 2024 Oct; 38(5):953-971. PubMed ID: 39060118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
    Spagnolo F; Croce E; Boutros A; Tanda E; Cecchi F; Mascherini M; Solari N; Cafiero F; Queirolo P
    Expert Rev Anticancer Ther; 2020 May; 20(5):403-413. PubMed ID: 32326767
    [No Abstract]   [Full Text] [Related]  

  • 14. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
    Patel A; Skitzki J
    J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
    McKean MA; Amaria RN
    Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy for resectable melanoma.
    Sharon CE; Karakousis GC
    Clin Exp Metastasis; 2024 Aug; 41(4):461-464. PubMed ID: 38281255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
    Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
    Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
    Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical updates in neoadjuvant immunotherapy for melanoma before surgery.
    Saad M; Castellano E; Tarhini AA
    Expert Rev Clin Immunol; 2024 Aug; 20(8):927-943. PubMed ID: 37578289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.